Inhibrx Biosciences Stock (NASDAQ:INBX)

Forecast Ownership Financials Chart

Previous Close

$114.34

52W Range

$26.19 - $155.29

50D Avg

$97.93

200D Avg

$89.30

Market Cap

$1.66B

Avg Vol (3M)

$321.11K

Beta

3.67

Div Yield

INBX Company Profile

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

110

IPO Date

May 29, 2024

Website

INBX Performance

INBX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$1.30M	$200.00K	$1.80M
Operating Income	$-135.03M	$-331.45M	$-219.22M
Net Income	$-140.06M	$1.69B	$-241.36M
EBITDA	$-135.03M	$1.70B	$-206.69M
Basic EPS	$-9.04	$116.58	$-5.12
Diluted EPS	$-9.04	$116.58	$-5.12

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
NKTR	Nektar Therapeutics
RLAY	Relay Therapeutics, Inc.
IMTX	Immatics N.V.
ORIC	ORIC Pharmaceuticals, Inc.
ATAI	Atai Beckley Inc.
ELVN	Enliven Therapeutics, Inc.
SANA	Sana Biotechnology, Inc.
AMLX	Amylyx Pharmaceuticals, Inc.
CVAC	CureVac N.V.
SNDX	Syndax Pharmaceuticals, Inc.